Showing posts with label avian influenza. Show all posts
Showing posts with label avian influenza. Show all posts

Tuesday, June 16, 2026

Avian #Influenza #Report: June 7 - 13 '26 (Wk 24) (HK CHP, June 16 '26)

 


(...)

Avian influenza A(H9N2)

    ° The case involved a 2-year-old boy with onset on June 9, 2026. 

    ° The patient was admitted for treatment on June 10, 2026 and is currently in stable condition

    ° Epidemiological investigations revealed the case likely had indirect exposure to contaminated environment at a fresh provision shop selling live poultry in a wet market. 

    ° One sample collected from a metal tray placed at the bottom of a live chicken cage inside the shop for collecting chicken droppings tested positive for the H9 avian influenza virus. 

    ° The remaining 16 environmental samples tested negative. 

    ° Whole genome sequencing and analysis of the patient’s clinical specimens confirmed that all of the virus genes were avian in origin and no significant genetic variations were detected

    ° All identified contacts remained asymptomatic.

(...)

Source: 


Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk24.pdf

____

Monday, June 15, 2026

#HK CHP continues to actively follow up on a #human case of #H9N2 virus infection and reminds public of possibility of "twin-peaks" for seasonal #influenza and #COVID19 during summer

 


    The Centre for Health Protection (CHP) of the Department of Health (DH) today (June 15) continued to actively follow up on a case of human infection with influenza A (H9) in collaboration with the relevant government departments. 

    Following whole genome sequencing and analysis of the patient's clinical specimens, the virus strain was confirmed to be a low-pathogenic avian influenza A (H9N2) virus

    All of the virus genes were avian in origin and no significant genetic variations were detected

    The patient is currently in stable condition and all six of his household contacts have remained asymptomatic

    As the H9N2 avian influenza virus has long been present in local poultry with low mortality rate for birds, and that the H9N2 avian influenza virus involved in this case has not shown evidence of human-to-human transmission or significant genetic variation, the CHP currently assessed the risk of a local avian influenza pandemic as low

    Nevertheless, the CHP once again strongly urged the public to maintain good personal and environmental hygiene at all times, avoid contact with live poultry, birds or their droppings, thoroughly cook poultry meat and eggs before consumption, and wash hands thoroughly after visiting places where live poultry is sold, so as to reduce the risk of avian influenza infection.

    In addition, with the recent rise in the activity of seasonal influenza and COVID-19, the CHP does not rule out the possibility that the activity of these two respiratory diseases will continue to rise in the coming months, leading to a "twin-peaks" phenomenon. Members of the public, particularly high-risk individuals, are advised to receive vaccination in a timely manner to reduce the risk of severe disease and death.

 

Human infection with influenza A (H9) virus

    In relation to the recent influenza A (H9) infection in a two-year-old boy, the Public Health Laboratory Services Branch of the CHP conducted whole genome sequencing and analysis of the virus, confirming that the virus strain is a low-pathogenic H9N2 avian influenza virus and that no significant genetic variations were detected. 

    The CHP has collected 17 environmental samples from the residence of the patient, the fresh provision shop at Wo Che Market he had visited, as well as a park in Fung Wo Estate

    One sample collected from a metal tray placed at the bottom of a live chicken cage inside the shop that was used to collect chicken droppings was tested positive for the H9 avian influenza virus. 

    The remaining 16 samples tested negative

    The CHP will conduct further analysis on the positive environmental sample. 

    The CHP believed that it is more likely for the boy to have contracted H9 avian influenza by touching a contaminated surface at the fresh food shop selling live poultry in Wo Che Market. Thorough disinfection and cleaning will be conducted at the fresh food shop in question.  

     The patient remains hospitalised in stable condition. His symptoms remain mild. Neither his family members nor the staff at the fresh provision shop concerned have developed any symptoms. The CHP has provided them with preventive medication and will continue to put them under medical surveillance.

     Based on the above epidemiological and virological evidence, the CHP assessed that the recent local case of infection has not changed the current risk level. The risk of an influenza pandemic due to local avian influenza remains low. The Government's response level under the "Preparedness Plan for Influenza Pandemic" remains at "Alert" level.

    Avian influenza viruses are generally classified as highly pathogenic or low pathogenic, and they mainly affect birds and poultry. Birds are also natural hosts for avian influenza viruses. 

    In occasional circumstances, cross-species transmission may occur when human come into close contact with infected poultry or contaminated environments. 

    However, there is currently no scientific evidence to suggest that the existing avian influenza viruses are capable of sustained and efficient human-to-human transmission. 

    No novel influenza virus arising from genetic reassortment between human seasonal influenza viruses and animal influenza viruses has been found either.

    Since 1999, a total of 11 cases of human influenza A (H9N2) have been recorded in Hong Kong, including five local cases and six imported cases. No fatal case has been recorded so far.

     According to data published by the World Health Organization (WHO), more than 160 cases of human infection with influenza A (H9) have been recorded globally in the past decade. The vast majority of patients presented with mild symptoms. As poultry is a natural host of the virus in many regions, sporadic human infections caused by contact with infected poultry or contaminated environments are expected to continue occurring worldwide.

     The CHP will continue to strengthen public education and publicity efforts to reduce the risk of avian influenza infection among the general public. A letter has been issued to all doctors in Hong Kong to update them on the latest situation regarding influenza A (H9), urging them to heighten vigilance and report any suspected cases.

 

Seasonal influenza and COVID-19

     Influenza activity in Hong Kong has increased in recent weeks but remains below the baseline level

    Based on past experience, Hong Kong may experience two influenza seasons each year. The onset of summer influenza season began at a later time than usual last year, and sustained a longer period, extending from early September last year to early January this year, resulting in the absence of the winter influenza season that traditionally occurs in the first quarter of each year. Since the summer influenza season typically occurs between July and August, it cannot be ruled out that it may begin earlier than usual this year.

     Regarding COVID-19, while overall local activity remains at a relatively low level, a slight increase has been recorded continually since early May. 

    The COVID-19 activity levels fluctuate, with an upsurge period seen approximately every six to nine months in recent years. Each upsurge is associated with changes in predominant circulating variants and a decline in community herd immunity. It has been nearly a year since the end of the last periodic upsurge of COVID-19 activity in Hong Kong, and it cannot be ruled out that the overall COVID-19 activity will rise further in the coming one to two months.

 

Government's vaccination programmes

     Vaccination remains the most effective way to prevent seasonal influenza, COVID-19 and its complications. It also reduces the risk of hospitalisation and death.

       The WHO has earlier announced its recommendations for the composition for seasonal influenza and COVID-19 vaccines in the upcoming season. Vaccine manufacturers are currently producing vaccines in accordance with the recommendations. A new batch of seasonal influenza vaccines will arrive in Hong Kong in this September, while COVID-19 vaccines will arrive in the fourth quarter.

     The COVID-19 vaccine provided under the Government's COVID-19 Vaccination Programme (the Programme) for children and adults will expire in mid-July and early September this year respectively. As the production and delivery of COVID-19 vaccines to Hong Kong with the new composition take time, eligible persons will not be able to receive free COVID-19 vaccines through the Programme for a short period during the transition period before a new batch of vaccines arrive in Hong Kong. Therefore, those in need are advised to make appointments as early as possible. Existing vaccination services will continue until the following dates:

         ° Individuals aged six months to 11 years: COVID-19 vaccination services will be available until July 10, 2026.

        ° Individuals aged 12 or above: COVID-19 vaccination services will be available until September 5, 2026.

     In addition, the shelf life of vaccines under the Government's Seasonal Influenza Vaccination (SIV) Programmes will expire at the end of July. The DH launched the 2025/26 SIV Programmes in September last year. With the government's active promotion and the cooperation of various stakeholders, over 2.03 million doses of vaccines have been administered. Members of the public who have not received vaccinations, particularly children, the elderly and chronic disease patients, should receive influenza vaccination as soon as possible.

     To prevent respiratory diseases, members of the public should maintain good personal, hand and environmental hygiene at all times. Members of the public with respiratory symptoms, even if the symptoms are mild, should wear a surgical mask, avoid crowded places and seek medical advice promptly. They should maintain hand hygiene before putting on and after removing a mask. When there is a rise in activity levels of respiratory diseases, high-risk persons should wear surgical masks when visiting public places. The general public should also wear a surgical mask when taking public transport or staying in crowded places.

     The public may visit the CHP's webpages for more information: Avian Influenza Webpage, Avian Influenza Report, COVID-19 Vaccination Programme, Seasonal Influenza Vaccination Programmes, Facebook page and Youtube channel. 

 

Ends/Monday, June 15, 2026 | Issued at HKT 22:10 | NNNN

Source: 


Link: https://www.info.gov.hk/gia/general/202606/15/P2026061500852.htm?fontSize=1

____

#Bhutan - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) (#poultry) - Immediate notification

 


A poultry farm in Samdrupjongkhar Region.

Source: 


Link: https://wahis.woah.org/#/in-review/7623

____

#Denmark - #Influenza A #H5 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


According to article 10.4.1.4 of the Terrestrial Animal Health Code, Member Countries should not impose bans on the trade in poultry commodities in response to notification on the presence of any influenza A virus in birds other than poultry.

A wild black-headed gull in Stevns.

Source: 


Link: https://wahis.woah.org/#/in-review/7614

____

#Sweden - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) (#poultry) - Immediate notification



{Helsingborg Region} This is a farm with mallards for restocking for game and breeding for this purpose. The mallards showed an increse in mortality. Euthanasia is ongoing. 

Source: 


Link: https://wahis.woah.org/#/in-review/7622

____

Saturday, June 13, 2026

#Genomic #wastewater #surveillance of seasonal and #zoonotic #influenza A viruses in #California during the 2024-2025 flu season

 


Abstract

Wastewater genomic surveillance provides an opportunity to detect human and animal influenza A virus (IAV). We aimed to implement an IAV genomic surveillance framework agnostic to subtype, which enables recovery of IAV from multiple hosts and estimation of proportions across subtypes. We conducted IAV genomic surveillance in wastewater during the 2024-2025 flu season at multiple sites in California and compared these data with available human clinical IAV sequences and test positivity. We applied a custom whole-genome, multi-host IAV probe enrichment panel and adapted our custom expectation-maximization (EM) algorithm to deconvolute IAV mixtures in wastewater and infer subtype relative abundances. Absolute IAV concentrations were quantified using RT-PCR-based assays. H5N1 wastewater and clinical sequences were further characterized by constructing a whole-genome maximum-likelihood phylogenetic tree. Finally, we performed variant analysis to examine amino acid substitutions detected in wastewater. Our IAV probe enrichment method and EM algorithm successfully enriched all eight segments of three circulating IAV subtypes and accurately estimated subclade relative abundances for mixed IAV samples. Seasonal human H1N1pdm09 and H3N2 were detected throughout the study period from both wastewater and clinical sequencing data, with H1N1 subclades 6B.1A.5a.2a.1 and 6B.1A.5a.2a co-circulating, and H3N2 dominated by subclade 3C.2a1b.2a.2a.3a.1. Wastewater surveillance consistently detected H5N1 clade 2.3.4.4b across three monitored wastewater sites, while clinical H5N1 detections, from anywhere in CA, were sporadic and rare. Whole-genome phylogenetic analysis revealed that wastewater H5N1 sequences clustered with reference sequences associated with dairy cow and avian infections, while all human clinical H5N1 sequences clustered exclusively with reference sequences associated with dairy cow infections. Amino acid substitutions were identified across viral segments, and no mutations associated with mammalian adaptation were observed from wastewater samples.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.06.10.26355323v1

____

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, June 13 '26)

 


    Arch Virol

  1. SMATTI MK, Al-Khatib H, Suleman M, Nizar M, et al
    Functional and structural characterization of the SARS-CoV-2 spike N481K mutation.
    Arch Virol. 2026;171:198.
    PubMed         Abstract available


    J Infect

  2. HARRIS R, Thirard R, McBrien C, Middleditch A, et al
    Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial.
    J Infect. 2026 Jun 4:106784. doi: 10.1016/j.jinf.2026.106784.
    PubMed         Abstract available

  3. CORRAO G, Sguazzini E, Gori A, Monti E, et al
    All-cause mortality within seven days of COVID-19 vaccination: A matched cohort and self-controlled case series study in Lombardy, Italy.
    J Infect. 2026;93:106769.
    PubMed         Abstract available

  4. GUINOVART LJ, Westrhenen SEMH, Schuurman R, Bruijning-Verhagen PCJL, et al
    Symptomatology of SARS-CoV-2 versus seasonal coronavirus infection in healthy young children.
    J Infect. 2026 May 20:106762. doi: 10.1016/j.jinf.2026.106762.
    PubMed         Abstract available


    J Infect Dis

  5. LIU F, Gross FL, Li Z, House SL, et al
    Birth cohort effects in adults associated with influenza A(H1N1)pdm09 vaccine effectiveness.
    J Infect Dis. 2026 Jun 8:jiag294. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  6. LIU Z, Fan M, Zeng Y, Zheng Y, et al
    Gga-miR-92-targeted TNFRSF1B inhibits the replication of influenza A virus by degrading TRAF3.
    J Virol. 2026 Jun 12:e0067426. doi: 10.1128/jvi.00674.
    PubMed         Abstract available

  7. XU S, Zhang Q, Xie X, Zhou M, et al
    A neutralizing nanobody targeting a conserved lateral patch on HA1 confers protection against multiple H7 avian influenza viruses.
    J Virol. 2026 Jun 11:e0056326. doi: 10.1128/jvi.00563.
    PubMed         Abstract available

  8. PENG M, Liu L, Li X, Yu X, et al
    Pre-pandemic contraction, phase-specific rate variation, and site-specific antigenic adaptation shape influenza A(H3N2) evolutionary dynamics in Hubei, China.
    J Virol. 2026 Jun 10:e0055626. doi: 10.1128/jvi.00556.
    PubMed         Abstract available


    PLoS Comput Biol

  9. LIN Z, Gao Y, Sun W
    Supervised deep learning with gene functional annotation for cell classification.
    PLoS Comput Biol. 2026;22:e1014327.
    PubMed         Abstract available

  10. KWON J, Li K, Warren JL, Pandya S, et al
    Utilizing virus genomic surveillance to predict vaccine effectiveness.
    PLoS Comput Biol. 2026;22:e1014329.
    PubMed         Abstract available


    PLoS One

  11. TAM VCW, Yeung NCY, Kwok AWL
    Getting over the hurdles to save lives: Incorporating perceived barriers into theory of planned behaviour (TPB) model to predict stated intention among Hong Kong trained laymen.
    PLoS One. 2026;21:e0350392.
    PubMed         Abstract available

  12. KONDO K, Morita I, Sakuma S, Ohsawa I, et al
    Changes in tobacco sales before, during, and after the COVID-19 pandemic in Japan: An interrupted time series analysis.
    PLoS One. 2026;21:e0350820.
    PubMed         Abstract available

  13. WOODGATE RL, Mary-Quigley L, Bell A, Bennett M, et al
    Youth's mental health journeys through the COVID-19 pandemic using arts-based methods in virtual environments.
    PLoS One. 2026;21:e0349860.
    PubMed         Abstract available

  14. KARAMI B, Rezaeian S, Bagherinia M, Shakiba E, et al
    Social support and health related quality of life among older people in covid-19 pandemic: The mediating role of resilience.
    PLoS One. 2026;21:e0342982.
    PubMed         Abstract available

  15. YANG RJ, Wang M, Lyu L, You JL, et al
    Pathogen spectrum and epidemiology of respiratory tract infections in Quzhou, Eastern China, from November 2023 to July 2024: A post?COVID?19 surveillance study.
    PLoS One. 2026;21:e0346441.
    PubMed         Abstract available

  16. BOLSHOV O, Chumachenko D
    Reinforcement learning for policymaking in epidemic control: A scoping review.
    PLoS One. 2026;21:e0351176.
    PubMed         Abstract available

  17. LIU C, Liu H, Wei Y, Ye J, et al
    Modeling the effects of meteorological factors and media-driven public awareness on seasonal influenza outbreaks.
    PLoS One. 2026;21:e0342962.
    PubMed         Abstract available

  18. LIU F, Lai T, Xu W, Li G, et al
    ViralMultiNet: A structure-aware multimodal framework for viral protein function prediction in wastewater surveillance.
    PLoS One. 2026;21:e0349393.
    PubMed         Abstract available

  19. MOUNCHID PM, Shukla S, Steinert JI
    The interplay of economic shocks and cultural practices in child marriage: Comparative evidence from India and Zambia during the COVID-19 pandemic.
    PLoS One. 2026;21:e0346851.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  20. ZHU Z, Fragkias M, Suh JW, McCoshan E, et al
    The Urban Pulse: Diagnosing the urbanization process as spiky, cyclical, and asynchronous.
    Proc Natl Acad Sci U S A. 2026;123:e2537770123.
    PubMed         Abstract available

  21. SKELLY AN, Fan C, Keeffe JR, Okten AB, et al
    mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.
    Proc Natl Acad Sci U S A. 2026;123:e2536870123.
    PubMed         Abstract available


    Vaccine

  22. WU X, Tao Y, Sun Y, Chen J, et al
    Cost-effectiveness of free influenza vaccination policy for Chinese older adults: a modeling analysis using real-world data.
    Vaccine. 2026;88:128782.
    PubMed         Abstract available

  23. BIETZ A, Sandow P, Hartmann C, Steffan L, et al
    Real-time in-season monitoring of adult influenza vaccination coverage rates in Germany: results from a repeated cross-sectional online survey.
    Vaccine. 2026;88:128765.
    PubMed         Abstract available

  24. SONG L, He G, Cui Y, Tan R, et al
    Optimized flagellin enhances systemic and mucosal immune responses induced by SARS-CoV-2 virus-like particle vaccines.
    Vaccine. 2026;87:128767.
    PubMed         Abstract available

  25. FAIJUE DD, Bouaddi O, Segui AO, Morias B, et al
    Catch-up and life-course vaccination policies for adult and adolescent migrants in low-and-middle income countries: A policy analysis.
    Vaccine. 2026;85:128645.
    PubMed         Abstract available

  26. FORNS J, Pajouheshnia R, Aurelius T, Bouck Z, et al
    Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study.
    Vaccine. 2026;86:128723.
    PubMed         Abstract available

  27. POWELL A, Suwalowska H, Sankoh O, Guo C, et al
    Recent enough to matter: Perceived temporal proximity, anxiety, and COVID-19 vaccine intent.
    Vaccine. 2026;85:128717.
    PubMed         Abstract available

  28. DALEXIS RD, Beogo I, Kibret TC, Cenat JM, et al
    Racial disparities in coverage and determinants of childhood diphtheria, tetanus, and pertussis (DTaP) vaccination in Canada: a post-COVID-19 pandemic analysis.
    Vaccine. 2026;85:128679.
    PubMed         Abstract available

  29. KOIRALA A, Prasad SA, Tjiam MC, Britton PN, et al
    SARS-CoV-2 Ancestral and Omicron variant immunity in Australian children in 2023, a seroprevalence study.
    Vaccine. 2026;85:128705.
    PubMed         Abstract available

  30. XU Y, Nyberg F, Marking U, Gisslen M, et al
    Rare adverse events after COVID-19 vaccination among Swedish older adults-evidence from a nationwide register-based study.
    Vaccine. 2026;85:128724.
    PubMed         Abstract available

  31. DANCHIN M, Rak A, Vasiliadis S, Wang B, et al
    Maternal preferences for infant respiratory syncytial virus (RSV) preventives: an Australian discrete choice experiment.
    Vaccine. 2026;85:128710.
    PubMed         Abstract available

  32. KOHLI M, Maschio M, Lee A, Kissler S, et al
    The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission model.
    Vaccine. 2026;85:128687.
    PubMed         Abstract available

  33. TRANG TPH, Bazelier MT, Klungel OH, Bots SH, et al
    Quality and methodological heterogeneity of COVID-19 vaccine safety studies focusing on the myocarditis safety signal: A systematic review, meta-analysis and meta-regression.
    Vaccine. 2026;85:128722.
    PubMed         Abstract available

  34. WANG R, Zhao Y, Yang J, Luo R, et al
    Systemic BCG administration induces transcription factor signature in CD4(+) T cells that cooperates with IL-12 signaling to drive antiviral Th1 differentiation.
    Vaccine. 2026;85:128720.
    PubMed         Abstract available


    Virology

  35. KOVACS E, Rios Carrasco M, Guerreiro Cabana MF, de Vries RP, et al
    H5N1 2.3.4.4b HA E190D and Q226H mutations, picked up as minority variants in a patient, result in an inability to bind sialic acid.
    Virology. 2026;621:110949.
    PubMed         Abstract available


    Virus Res

  36. TJARNHAGE E, Vatsveen TK, Raki M, Nemazee D, et al
    Repurposing ALK Inhibitors as Influenza and Corona Virus Antivirals Targeting Lymphocyte Tyrosine Kinase (LTK).
    Virus Res. 2026 Jun 9:199759. doi: 10.1016/j.virusres.2026.199759.
    PubMed         Abstract available

Friday, June 12, 2026

#HK PRC SAR, CHP investigates a #human case of #influenza #H9 #infection (June 12 '26)

 


    The Centre for Health Protection (CHP) of the Department of Health (DH) is today (June 12) investigating a case of human infection with influenza A (H9) in collaboration with relevant departments. 

    The patient is a two-year-old boy. His condition has remained mild and he is currently in stable condition

    The CHP will send a letter to all doctors in Hong Kong to update them on the latest developments regarding avian influenza A and to urge them to remain vigilant and report any suspected cases.

 

Case information

    The boy lives in Sha Tin District. He developed a fever and mild diarrhoea on June 9. On the following day (June 10), he was brought to Prince of Wales Hospital and was admitted for treatment. His clinical specimen tested positive for the influenza A (H9) virus by the Public Health Laboratory Services Branch (PHLSB) of the CHP. The subtyping result is pending. His clinical diagnosis was novel influenza. He is currently in stable condition and has been admitted to an isolation ward at Princess Margaret Hospital for treatment.

      The CHP's preliminary investigation revealed that the patient had no travel history during the incubation period. 

    The case has been classified as a locally acquired case. 

    The patient does not attend school or receive daycare services. 

    He is primarily cared for by his family members and spends most of his time at home or nearby. 

    His household does not keep poultry

    According to information provided by his family members, he has neither consumed undercooked poultry nor come into contact with any patients

    In early June, one of his family members took him to Wo Che Market on two occasions. During these visits, the patient stayed at a fresh provision shop in the market that sells live chickens to watch the poultry and touched the surroundings of the fresh provision shop

    The CHP conducted an investigation with the Food and Environmental Hygiene Department (FEHD) and collected environmental samples from the shop concerned. 

    The shop staff remained asymptomatic

    The patient has six household contacts and they remain asymptomatic so far. 

    The CHP has provided them with preventive medication and put them under medical surveillance.

      The CHP is continuing to investigate the source of infection of the case and is conducting whole genome sequencing of the virus sample. The CHP will also report the case to the World Health Organization (WHO).

      Humans are primarily infected with the influenza A virus through direct contact with infected poultry or through indirect contact with environments contaminated by their droppings. 

    The CHP's epidemiological investigation indicated that the patient had visited a location where live poultry was sold. It cannot be ruled out that the patient was infected through indirect contact with a contaminated environment at the wet market. 

    As young children have weaker immune systems and are incapable of maintaining good hand hygiene, the CHP advised parents to avoid taking young children to places where live poultry is sold. 

    Transporting poultry may contaminate the ground and the surrounding environment. 

    As young children are shorter in height and easy to be in contact with the surrounding environment, they are at greater risk of coming into contact with poultry droppings or contaminated areas.

      In the past ten years, the WHO has received reports of a total of over 160 cases of human infection with influenza A (H9) worldwide

    To date, most case of human infection with influenza A (H9) have presented with only mild clinical illness

    According to the WHO's risk assessment, the influenza A (H9) virus has not acquired the ability for sustained human-to-human transmissions.

 

Government's comprehensive follow-up actions

    Novel influenza A infection, including influenza A (H9), is a notifiable infectious disease in Hong Kong

    Compared to other highly pathogenic avian influenza strains such as H5N1 and H7N9, influenza A (H9) is a low-pathogenic avian influenza strain that causes milder illness

    Excluding the aforementioned case, 10 cases of influenza A (H9N2) have been reported since 1999, including four locally acquired cases and six imported cases

    No deaths have been recorded so far. 

    In response to the latest local case, the CHP will issue a letter to all doctors in Hong Kong, reminding them of the latest situation of influenza A (H9), and urging them to remain vigilant and report any suspected cases.

      Sporadic cases of human infection with avian influenza occur from time to time internationally. Although the current risk of an outbreak is low, the Hong Kong Special Administrative Region Government has consistently implemented preventive measures, including a disease surveillance system, the implementation of livestock control measures at farms, markets and ports, in order to prevent avian influenza.

      The PHLSB of the CHP comprises laboratories with high biosafety standards, capable of conducting, testing for high-risk pathogens, and which also possess sufficient testing and genetic analysis capabilities and facilities. Hong Kong currently has sufficient reserve of antiviral medications.

 

Preventive measures to be taken by the public

    Humans are primarily infected with the avian influenza A virus through contact with infected birds, poultry or other animals (whether alive or dead), or through surfaces or environments contaminated with saliva, mucous and animal faeces (such as wet markets and live poultry markets). 

    The virus has very low transmissibility among humans. People who have close contact with live poultry are more susceptible to contracting avian influenza. The elderly, children and people with chronic illnesses have a higher risk of developing complications such as bronchitis and pneumonia, if infected. 

    Members of the public should remain vigilant and take the following measures to prevent avian influenza:

         ° Avoid contact with poultry, birds or their droppings. If contact has been made, thoroughly wash hands with soap and water;

        ° Poultry and eggs should be thoroughly cooked before eating;

        ° Perform hand hygiene at all times, especially before touching the mouth, nose or eyes; after contact with animals or their living environments; after touching public installations such as handrails or doorknobs; or when hands are contaminated with respiratory secretions, such as after coughing or sneezing;

        ° Cover the mouth and nose with tissue paper when sneezing or coughing. Dispose of soiled tissues into a lidded rubbish bin, then wash hands thoroughly;

        ° When having respiratory symptoms, wear a surgical mask, do not go to work or school, avoid crowded places and seek medical advice promptly;

        ° Avoid crowded public places or areas with poorly ventilated; high-risk individuals may consider putting on a surgical mask when staying in such places; and

        ° Travellers returning to Hong Kong from areas affected by avian influenza outbreaks should consult doctors promptly if they have flu-like symptoms, and inform the doctor of the recent travel history and wear a surgical mask to help prevent spreading of the disease.

    The public may visit the CHP's webpages for more information: Avian Influenza Webpage, Avian Influenza Report, Avian influenza statistics and affected areas around the world, Facebook page and Youtube channel. 

 

Ends/Friday, June 12, 2026 | Issued at HKT 22:19 | NNNN

Source: 


Link: https://www.info.gov.hk/gia/general/202606/12/P2026061200852.htm?fontSize=1

____

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, June 12 '26)

 


{Excerpt}

(...)

Time Period: May 31, 2026 - June 06, 2026

    -- A(H5) Detection3 site(s) (0.7%)

    -- No Detection440 site(s) (99.3%)

    -- No samples52 site(s)


{Click on Image to Enlarge}



(...)

Source: 


Link: https://www.cdc.gov/wastewater/emerging-viruses/h5.html?

____

A neutralizing #nanobody targeting a conserved lateral patch on HA1 confers #protection against multiple #H7 avian #influenza viruses

 


ABSTRACT

Human infections with H7 avian influenza viruses (AIVs) have been documented globally, involving multiple subtypes and geographic regions. However, effective therapeutics targeting H7 influenza viruses remain limited. Here, a panel of nanobodies targeting the HA1 domain of hemagglutinin (HA) was identified by yeast two-hybrid (Y2H) screening, and six candidates were subsequently validated to exhibit hemagglutination inhibition (HI) activity. Of these, a subset also displayed virus microneutralization (MN) activity, while all showed binding activity in ELISA assays. Among them, Nb74 exhibited inhibitory activity against four Chinese recombinant vaccine-matched strains (Rv1–Rv4), which were generated based on the HA sequences of the corresponding inactivated vaccine strains H7-Re1 to H7-Re4. The HI-IC50 values were 0.23, 0.57, 3.65, and 43.75 µg/mL, respectively, and the MN-IC50 values for Rv1–Rv3 were 0.02, 0.06, and 1.09 µg/mL. It also retained activity against diverse clinical isolates although HI potency varied among strains. In mouse challenge experiments, intratracheal administration of Nb74 conferred robust protection, achieving 100% and 80% survival against Rv1 and Rv2, respectively, when administered prophylactically (2 mg/kg) or therapeutically (4 mg/kg). Treated mice showed accelerated body weight recovery, reduced lung viral load, and alleviated pulmonary pathology. Mechanistic analyses indicated that Nb74 neutralizes virus by blocking viral attachment to the host. Furthermore, combined hydrogen-deuterium exchange mass spectrometry (HDX-MS) with escape mutant analysis mapped its epitope to a conserved lateral patch on the HA1 subunit, consistent with a conformational epitope. Overall, these results demonstrate the therapeutic promise of intratracheally delivered Nb74 and provide insights for H7 AIVs vaccine design.

Source: 


Link: https://journals.asm.org/doi/10.1128/jvi.00563-26

____

Immunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 #H5N8 -like #influenza #vaccine in adults: Phase 1/2, observer-blinded, randomized trial

 


ABSTRACT

Influenza pandemics arise from novel influenza A viruses. Recent emergence of a new clade (2.3.4.4.b) of the highly pathogenic H5N1 in animals and humans highlighted its pandemic potential. We evaluated the immunogenicity and safety of GSK’s AS03-adjuvanted H5N8 vaccine in adults. In this phase 1/2, observer-blinded, age-stratified, randomized trial, healthy US adults (age, ≥18 y) received two intramuscular doses of hemagglutinin antigen (3.75 or 7.50 μg) with AS03A or AS03B, administered 21 d apart. Immunogenicity – seroprotection rates (SPRs), seropositivity, geometric mean titers (GMTs), geometric mean fold rise (GMFR), and seroconversion rates (SCRs) – was evaluated on day 43 using hemagglutination inhibition (HI) and microneutralization (MN) assays. Safety was monitored throughout the study. Of 520 enrolled participants, 518 were vaccinated. On day 43, the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research criteria for influenza vaccines were met. HI SPRs, seropositivity rates, SCRs, GMTs, and GMFR appeared to be higher in the AS03A vs AS03B group. Immune responses were generally higher in younger (aged 18–64 y) vs older (aged ≥65 y) adults. Immune responses were also detected in MN assays, with a correlation between HI and MN responses on day 43 across age groups and vaccine formulations. Safety was acceptable, with no increase in adverse events post-dose 2. Reactogenicity appeared more common in younger adults. The antigen-sparing potential of AS03 was demonstrated, with an acceptable safety profile. The benefit/risk profile was favorable for all formulations tested, including 3.75 µg AS03A (licensed in the US).


ClinicalTrials.gov registration: NCT05975840.

Source: 


Link: https://www.tandfonline.com/doi/full/10.1080/21645515.2026.2649314

____

#Germany - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


A flock of backyard laying hens in Bayern Region.

Source: 


Link: https://wahis.woah.org/#/in-review/7616

____

Thursday, June 11, 2026

Evaluation of #antiviral #treatments for highly pathogenic avian #influenza virus #infections in #feline species

 


Abstract

In 2020, highly pathogenic avian influenza (HPAI) isolates from clade 2.3.4.4b emerged in Europe and spread globally, including in bovine hosts in the USA. Viruses from this clade cause minimal disease in dairy cattle, characterized by decreased milk production but low mortality rates. Infections have also occurred in feline hosts. In contrast to cows, infection of cats (and closely related species, including skunks and foxes) can result in severe neurological signs and mortality. Documented feline H5N1 infections from clade 2.3.4.4.b have a mortality rate of approximately 80% following rapid onset of clinical signs. No antiviral compounds have been tested in an experimental feline model; however, anecdotal clinical evidence suggests early treatment with oseltamivir may improve outcomes in felines with HPAI. Here, we show the in vitro efficacy of several influenza inhibitors in feline glial astrocyte (PG-4) and kidney (CRFK) cell culture models using the clade 2.3.4.4.b virus Tx2/24 (H5N1). The neuraminidase inhibitor oseltamivir carboxylate did not effectively inhibit viral replication in either cell line. The cap-dependent endonuclease inhibitor baloxavir exhibited the strongest inhibition of this virus, with EC50 values of 30 nM in PG-4 and 1 μM in CRFK cells. Amantadine and rimantadine, M2 ion channel inhibitors, were unable to completely inhibit viral replication in either cell line at any concentration utilized. The broad-spectrum nucleoside analog GS-441524 demonstrated little to no inhibition of viral replication in either cell line. Additionally, the mutagenic NHC analogs EIDD-1931 and EIDD-2801 successfully inhibited viral replication at the maximum tested concentration of 100 μM but exhibited significant cytotoxicity. Our findings suggest that baloxavir should be considered by veterinary clinicians as the first-line drug of choice when presented with felines or other species infected with HPAI.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Cornell Feline Health Center, Ithaca, US

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.06.09.730954v1

____

Tuesday, June 9, 2026

Avian #Influenza #Report - May 31 – June 6 '26 (Wk 23) (#HK CHP, June 9 '26): 2 new human #H5N1 virus cases in #Bangladesh, #India; 1 new case of H9N2 virus in #China



(...)

    -- Bangladesh

        ° Avian influenza A(H5N1) 

            ° Sylhet Division

                - The case involved a child with symptom onset on March 27, 2026.  

                - The patient was admitted to a hospital on March 28 for treatment of measles with bronchopneumonia, and was discharged on March 30. 

                - Epidemiological investigations revealed the case had exposure to household poultry.   

                - No additional cases were reported among the identified contacts.  

    -- India

        ° Avian influenza A(H5N1)

            - The case involved a child who developed symptoms and was admitted to a hospital on March 19, 2026. 

            - The patient was discharged on March 23.  

            - Epidemiological investigations revealed the case likely had indirect exposure to poultry. 

            - No additional cases were reported among the identified contacts. 

        -- China

            ° Avian influenza A(H9N2)

                ° Yunnan Province

                    - A 4-year-old boy with onset on May 17, 2026. 

(...)


Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk23.pdf

____


#Honduras - #Influenza A #H5 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


{Click on Image to Enlarge}

By Charles J. Sharp - Own work, from Sharp Photography, sharpphotography.co.uk, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=129540572

____

    On June 3, 2026, the Regional Office of the National Agri-Food Health and Safety Services (SENASA) was notified of an unusual mortality event among wild birds in the community of El Higuito, Talgua, in the department of Lempira, an area bordering the department of CopĂ¡n

    Following the official reception of the notification and the collection of samples, the Central Laboratory (IHIMV) confirmed on June 5, 2026, via RT-PCR, the presence of Avian Influenza Type A Subtype H5

    The event involved the mortality of black vultures (Coragyps atratus), which poses a potential risk to small-scale and commercial poultry farming in the area. 

    As an immediate response, the contingency team was activated, carrying out the collection, incineration, and sanitary burial of 136 wild birds found dead, with the aim of reducing the environmental viral load and limiting the spread of the pathogen. 

    Additionally, coordination with poultry sector authorities was strengthened to implement preventive and biosecurity measures. 

    Epidemiological surveillance has been intensified both in the outbreak zone of the event and around the outbreak. 

    Through door-to-door monitoring conducted in six surrounding communities, 14,282 backyard birds were inspected without identifying clinical signs compatible with avian influenza or mortality events. 

    These findings indicate that, to date, there is no evidence of transmission to domestic poultry

    Given the epidemiological risk associated with the circulation of the virus in wildlife, active surveillance will continue in neighbouring communities and municipalities, along with the strengthening of biosecurity measures and risk communication directed at producers and the general public. 

    Follow-up reports will be submitted to provide periodic updates.

Source: 


Link: https://wahis.woah.org/#/in-review/7612

____

Saturday, June 6, 2026

The #canine respiratory #epithelium is a permissive #ecosystem for #influenza interspecies #transmission and emergence

 


Abstract

The outcome of virus spillover ranges from dead-end infections to pandemics and is underpinned by host-pathogen interactions as well as evolutionary and epidemiological processes. The emergence of novel influenza A viruses (IAVs) has been associated with reassortment events involving multiple species, highlighting the importance of reservoir and intermediate hosts in viral emergence. Highly pathogenic H5N1 IAVs of the 2.3.4.4b genotype have caused a panzootic affecting a broad range of mammals. The role of dogs -arguably the most popular companion animal and a natural host of IAVs- in the ecology of IAVs under this new zooepidemiological scenario is unknown. To address this, we characterised the glycome of the dog respiratory epithelium, infected canine tracheal explants with multiple IAVs (including canine H3N2 and H3N8, equine H3N8, avian H3N8 and H5N1, swine H1N1, human H1N1 and H3N2, and bovine H5N1 viruses), and determined their cellular tropism. We show that the respiratory tract of dogs presents abundant sialylated glycans known to act as IAV receptors. Further, most IAVs (including 2.3.4.4b viruses) infected and replicated in dog tracheas, targeting mainly ciliated cells. Serological testing showed evidence of influenza spillover infections in dogs from the UK. Overall, our results show that the canine respiratory tract can provide a suitable environment for the generation of new IAVs. Given the multi-host contact networks of dogs in nature, they could act as recipients, bridging hosts, and/or mixing vessels for multiple IAV lineages, playing a central role in the ecology of influenza emergence.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Medical Research Council, https://ror.org/03x94j517, MR/Y03368X/1, MC_UU_0034/2, MC_UU_0034/3

Biotechnology and Biological Sciences Research Council, BB/Y007093/1, BB/Y007298/1, BBS/E/PI/230001A, BBS/E/PI/230002A, BBS/E/PI/230002B, BBS/E/PI/230001C

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.06.04.730051v1

____

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, June 6 '26)

 


    Arch Virol

  1. PERDANA WY, Tsuneki-Tokunaga A, Rahmi KA, Hinay AA Jr, et al
    In vitro efficacy of anti-influenza active compounds against clinical isolates with high growth capability.
    Arch Virol. 2026;171:200.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  2. SHAO S, Dong ZY, Kang ZY, Zhang H, et al
    Dynamic regulation-based stabilizing mutations are highly effective for designing RSV pre-fusion F mRNA vaccines.
    Biochem Biophys Res Commun. 2026;825:153958.
    PubMed         Abstract available


    Epidemiol Infect

  3. SANE J
    Rebuilding trust in public health: Beyond polarization.
    Epidemiol Infect. 2026;154:e71.
    PubMed         Abstract available

  4. HASSELL K, Andrews N, Dabrera G, Kall M, et al
    Acute COVID-19 mortality in England in the omicron era: a national-level matched cohort study.
    Epidemiol Infect. 2026;154:e70.
    PubMed         Abstract available


    J Infect Dis

  5. PRASERT K, Praphasiri P, Ditsungnoen D, Naosri S, et al
    Risk of hospitalization related to influenza A(H3N2) virus subclade K, Thailand, June-December 2025.
    J Infect Dis. 2026 May 31:jiag283. doi: 10.1093.
    PubMed         Abstract available


    J Neurosurg Pediatr

  6. ANDERSON MG, Pindrik J, Michelow IC, Anuar A, et al
    Pediatric sinogenic and otogenic intracranial infections requiring neurosurgical intervention: a North American multicenter study in the era of COVID-19.
    J Neurosurg Pediatr. 2026;37:621-631.
    PubMed         Abstract available


    J Virol


  7. CEIRR Risk Assessment Pipeline executive reports on H5N1 highly pathogenic avian influenza 2.3.4.4b, swine H1 1B.2, and H9N2 low pathogenicity avian influenza B4.7.2.
    J Virol. 2026 Jun 3:e0054526. doi: 10.1128/jvi.00545.
    PubMed         Abstract available

  8. STEARNS K, Marcink T, Pawlack E, Sobolik EB, et al
    Human parainfluenza virus 3 fusion protein cleavage: a key determinant of infection and spread.
    J Virol. 2026 Jun 3:e0212625. doi: 10.1128/jvi.02126.
    PubMed         Abstract available

  9. TURNER AH, Jaffrani SA, Kubinski HC, Ajayi DP, et al
    Rab11B is required for binding and entry of recent H3N2, but not H1N1, influenza A isolates.
    J Virol. 2026 Jun 2:e0211125. doi: 10.1128/jvi.02111.
    PubMed         Abstract available


    Pediatrics

  10. ROSTAD CA, Healy CM, Nayak JL, Parameswaran L, et al
    Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial.
    Pediatrics. 2026 May 4:e2025075223. doi: 10.1542/peds.2025-075223.
    PubMed         Abstract available


    PLoS One

  11. EKWUNIFE O, Mangenah C, Ngwira L, Corbett E, et al
    Economic barriers to diagnostic equity: A multi-country analysis of patient costs for rapid SARS-CoV-2 testing in sub-Saharan Africa.
    PLoS One. 2026;21:e0350288.
    PubMed         Abstract available

  12. HEMBERG M, Hansen AL, Storgaard J, Blay-Cadanet J, et al
    MAVS is important for antiviral defense against influenza A virus in a human respiratory epithelium model.
    PLoS One. 2026;21:e0350839.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  13. RIKANI A, Di Domenico L, Sabbatini CE, Navarro V, et al
    Resetting population mobility responses under repeated nonpharmaceutical interventions: Implications for hypothesized pandemic fatigue.
    Proc Natl Acad Sci U S A. 2026;123:e2533284123.
    PubMed         Abstract available

  14. PAPADAKI M, Pavlos E, Dubourdeau M, Bailif V, et al
    Polyunsaturated fatty acid-derived lipid mediator patterns determine viral pneumonia severity and risk for critical COVID-19.
    Proc Natl Acad Sci U S A. 2026;123:e2534726123.
    PubMed         Abstract available

  15. GRUNDY JG, Pujols-Beltran M
    Bilingualism predicts executive function resilience after COVID-19 in aging.
    Proc Natl Acad Sci U S A. 2026;123:e2532470123.
    PubMed         Abstract available


    Vaccine

  16. DE FIGUEIREDO A, Paterson P, Lin L, Mounier-Jack S, et al
    Changing socio-demographic determinants of seasonal influenza acceptance in England during the pandemic and a framework for predicting future acceptance.
    Vaccine. 2026;85:128629.
    PubMed         Abstract available

  17. DAS S, Tenaglia BM, Riley D, Speed S, et al
    BECC-adjuvanted hemagglutinin influenza vaccine promotes enhanced immunogenicity and protective efficacy.
    Vaccine. 2026;87:128774.
    PubMed         Abstract available


    Virus Res

  18. SEDAGHAT M, Najafi F, Khosravi Shademani F, Rezaeian S, et al
    Seasonal influenza vaccine and frequency of adverse events in health workers receiving two doses of AstraZeneca vaccine: a retrospective cohort study.
    Virus Res. 2026;369:199757.
    PubMed         Abstract available

My New Space

Most Popular Posts